Breast Cancer Update, Issue 4, 2019


BCU319

Interview with Hope S Rugo, MD

Track 1: Biology of triple-negative breast cancer (TNBC); implications for therapeutic decision-making
Track 2: Median overall survival estimates for patients with metastatic TNBC
Track 3: Survival outcomes for patients with metastatic ER-positive and HER2-positive breast cancer
Track 4: Case: A woman in her early 30s with localized TNBC receives neoadjuvant chemotherapy on the control arm of the I-SPY 2 trial
Track 5: Genetic testing for patients with TNBC
Track 6: Fertility preservation in young women undergoing therapy for breast cancer
Track 7: Perspective on the use of GnRH agonists for premenopausal women with TNBC
Track 8: Importance of providing support to patients coping with a diagnosis of TNBC
Track 9: I-SPY 2 trial: Neoadjuvant and personalized adaptive novel agents to treat breast cancer
Track 10: Novel agents under evaluation in the I-SPY 2 trial
Track 11: Investigation of immune checkpoint inhibitor combination approaches
Track 12: Cooling caps to reduce chemotherapy-related hair loss
Track 13: Use of frozen gloves and socks to lessen chemotherapy-induced peripheral neuropathy
Track 14: Coping with the side effects of chemotherapy
Track 15: Case: A woman in her early 60s with metastatic TNBC is treated with atezolizumab and nab paclitaxel
Track 16: Importance of accurately determining tumor of origin in patients who present with metastatic disease after diagnosis of multiple primary cancers
Track 17: Approach to genetic testing for women with metastatic TNBC
Track 18: Use of genetic test results in clinical decision-making
Track 19: Improvement in overall survival with atezolizumab and nab paclitaxel for patients with PD-L1-positive TNBC
Track 20: Response and tolerability of atezolizumab with nab paclitaxel on the IMpassion130 study
Track 21: Thyroid dysfunction associated with immune checkpoint inhibitors
Track 22: Biologic rationale for the investigation of immune checkpoint inhibitors in breast cancer
Track 23: Activity of anti-PD-1/PD-L1 antibodies in patients with breast cancer
Track 24: Design, eligibility and outcomes of the IMpassion130 study evaluating atezolizumab with nab paclitaxel as first-line therapy for advanced TNBC
Track 25: Therapeutic approach for patients with TNBC and BRCA mutations
Track 26: Case: A woman in her early 40s with a germline BRCA1 mutation receives chemotherapy followed by maintenance olaparib for metastatic TNBC
Track 27: Efficacy of olaparib and talazoparib for patients with advanced breast cancer and a germline BRCA mutation
Track 28: Tolerability profile of olaparib versus talazoparib
Track 29: Emerging data with the novel antibody-drug conjugates sacituzumab govitecan, trastuzumab deruxtecan and ladiratuzumab vedotin for advanced breast cancer

Interview with Melinda Telli, MD

Track 1: Case: A woman in her early 50s with de novo metastatic TNBC is enrolled on the IMpassion130 trial evaluating atezolizumab with nab paclitaxel
Track 2: Initial workup and genetic testing for patients with metastatic TNBC
Track 3: Risk of recurrence for patients with localized TNBC; patterns of metastasis
Track 4: Approach to PD-L1 testing for patients with TNBC
Track 5: Results of the Phase III IMpassion130 study of atezolizumab with nab paclitaxel for previously untreated advanced TNBC
Track 6: Clinical implications of the IMpassion130 study results
Track 7: Perspective on progression-free and overall survival outcomes with atezolizumab/nab paclitaxel
Track 8: Clinical experience with atezolizumab and nab paclitaxel as first-line therapy for advanced TNBC
Track 9: Tolerability of atezolizumab in the IMpassion130 trial
Track 10: Activity of single-agent pembrolizumab in patients with TNBC
Track 11: Emerging data with pembrolizumab in combination with chemotherapy for TNBC in the (neo)adjuvant setting
Track 12: Evaluation of anti-PD-L1 antibodies in the neoadjuvant setting
Track 13: Case: A woman in her late 20s with a family history of breast cancer and a germline BRCA mutation receives talazoparib and avelumab on a clinical trial for metastatic TNBC
Track 14: Efficacy and tolerability of platinum regimens for patients with TNBC
Track 15: Results from the OlympiAD (olaparib) and EMBRACA (talazoparib) trials for patients with HER2-negative advanced breast cancer and a germline BRCA mutation
Track 16: Activity and side-effect profile of olaparib versus talazoparib
Track 17: Ongoing investigation of the combination of anti-PD-1/PD-L1 antibodies and PARP inhibitors
Track 18: Sequencing PARP inhibitors for patients with PD-L1-negative breast cancer
Track 19: Use of PARP inhibitors for patients with breast cancer and mutations in DNA damage repair genes beyond BRCA
Track 20: Tolerability of PARP inhibitors for patients with germline BRCA mutations
 
FACULTY
 
Hope S Rugo, MD
Professor of Medicine
Director, Breast Oncology and
Clinical Trials Education
University of California
San Francisco Medical Center
UCSF Helen Diller Family
Comprehensive Cancer Center
San Francisco, California
 
Melinda Telli, MD
Associate Professor of Medicine
Stanford University School of Medicine
Leader, Breast Oncology
Clinical Research Group
Stanford Cancer Institute
Stanford, California
 
EDITOR
 
Neil Love, MD
Research To Practice
Miami, Florida